© 2003 European Society of Cardiology
Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs
Istituto di Cardiologia, Università degli Studi di Bologna, Azienda Ospedaliera S.Orsola-Malpighi, Bologna Via Massarenti 9, 40138 Bologna, Italy
* Corresponding author. Tel.: +39-51-349858; fax: +39-51-344859
 |
Abstract |
|---|
The possibility of using implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden death in selected high-risk patients has prompted a series of prospective controlled studies. Recently, the MADIT II study highlighted the possibility of effective primary prevention of sudden death in patients with coronary artery disease selected by straightforward clinical data and without expensive screening (electrophysiological study). For patients with previous myocardial infarction and low left ventricular ejection fraction (
30%), ICD implantation may reduce mortality risk by approximately 31% in the following 2 years. Implementation of this therapeutic strategy threatens to impact on public health-care spending. Possible cost-limiting mechanisms include price cuts because of increasing usage (market forces); identification of subgroups at higher risk of sudden death and use of cheaper devices with limited diagnostic and therapeutic options. Further long-term evaluation of the cost-effectiveness and cost-utility of ICDs should identify subgroups of patients for whom implantation is affordable despite current economic constraints. For heart failure patients, randomized controlled trials are currently evaluating the effects on overall survival of both conventional ICDs and devices with biventricular pacing capabilities. In this perspective, data from the COMPANION trial are expected to stimulate the use of devices with defibrillation back-up in candidates for biventricular pacing.
Key Words: Cardioverter-defibrillator • Coronary artery disease • Sudden death • Ventricular tachyarrhythmias
Received October 2, 2002; Revised April 17, 2003; Accepted May 15, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Boriani, M. Biffi, C. Martignani, C. Valzania, I. Diemberger, M. Bertini, G. Domenichini, M. Ziacchi, and A. Branzi Is cardiac resynchronization therapy cost-effective? Europace, November 1, 2009; 11(suppl_5): v93 - v97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boriani, M. Biffi, C. Martignani, I. Diemberger, C. Valzania, M. Bertini, and A. Branzi Expenditure and value for money: the challenge of implantable cardioverter defibrillators QJM, May 1, 2009; 102(5): 349 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Boriani, M. Biffi, A. Marziali, I. Diemberger, and C. Martignani A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance Europace, January 1, 2009; 11(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boriani, R. Ricci, T. Toselli, R. Ferrari, A. Branzi, and M. Santini Implantable cardioverter defibrillators: from evidence of trials to clinical practice Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I66 - I73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boriani, M. Biffi, C. Martignani, I. Mangat, F. Bokhari, D. Newman, M. Greene, V. Korley, and P. Dorian Letter Regarding Article by Bokhari et al, "Long-Term Comparison of the Implantable Cardioverter Defibrillator Versus Amiodarone: Eleven-Year Follow-Up of a Subset of Patients in the Canadian Implantable Defibrillator Study (CIDS)" * Response Circulation, January 25, 2005; 111(3): e26 - e26. [Full Text] [PDF]
|
|